USCLC Annual Workshop March 24, 2022

New and Emerging Treatments for Cutaneous T-cell Lymphoma: From Bench to Bedside

Thursday, March 24, 2022

Agenda

7:00 - 8:00	Breakfast
8:00 - 8:10	Welcome and Introduction *Wei Ai, University of California, San Francisco; *Stefan Schieke, University of Wisconsin; *Michi Shinohara, University of Washington
8:10 - 10:10	Updates on Current Therapies *Weiyun Ai, *Stefan Schieke, *Michi Shinohara
	Brentuximab and relevance of CD30 in CTCL Youn Kim, Stanford University
	Mogamulizumab Updates Michael Khodadoust, Stanford University
	HDAC-I - Updates and Combinations Regimens Francesca Montanari, Yale University
	Extracorporeal Photopheresis Sara Samimi, University of Pennsylvania
	Role Of Radiation Therapy in the Treatment Of CTCL Austin Kirschner, Vanderbilt University
	Retinoids - Practice Patterns and Managing Side Effects Michi Shinohara, University of Washington
	Chemotherapy and Stem Cell Transplant in CTCL Francine Foss, Yale University
10:10 - 10:30	Panel Discussion & Audience Polling

*Wei Ai, University of California, San Francisco; *Stefan Schieke, University of Wisconsin; *Michi Shinohara, University of Washington Practical Applications, Caveats, and Sequence of Therapies; Impact of COVID

10:30 - 10:50 Break + Virtual Poster Viewing

USCLC Annual Workshop March 24, 2022

New and Emerging Treatments for Cutaneous T-cell Lymphoma: From Bench to Bedside

10:50 - 11:20 Abstract Presentations - Part 1

*Michael Girardi, Yale University

An Implantable Microdevice (IMD) for In Situ Drug Screening in T-Cell Lymphoma **Cecilia Larocca**, Harvard Medical School

Gene Expression Changes in SS Patients Following Mogamulizumab Treatment Refines Biomarker and Immune Profile **Alanna Davis**, University of Arkansas

Characteristics of the T-cell repertoire in the skin, but not blood, distinguishes large cell transformed mycosis fungoides from its non-transformed counterpart **Laura Gleason**, Thomas Jefferson University

11:20 - 12:20 Zackheim Lecture

*Ellen Kim, University of Pennsylvania

Alain Rook, University of Pennsylvania

- 12:20 1:10 Lunch & Business Meeting
- **1:10 1:40** Abstract Presentations Part **2**

*Oleg Akilov, University of Pittsburgh

Characterizing visceral cutaneous T-cell lymphoma: a single-center retrospective analysis **Tony Zhuang**, Emory University

Primary Cutaneous Marginal Zone Lymphoma: A Systematic Review **Brooke Kennamer**, Boston University

Immune-related adverse events from mogamulizumab in cutaneous T-cell lymphoma: A singlecenter experience Abdulhadi Jfri, Harvard Medical School

Abdulliau JIII, Haivai u Medicai Scho

1:40 – 2:52 Bench to Bedside - Part 1

*Francine Foss, Yale University

Targeting metabolic drivers of disease progression in lymphoid cancers **Stefan Schieke**, University of Wisconsin-Madison

USCLC Annual Workshop March 24, 2022

New and Emerging Treatments for Cutaneous T-cell Lymphoma: From Bench to Bedside

<i>Mouse Models of CTCL</i> Weivun Ai , University of California, San Francisco
Anti-CD47 IMT in Mycosis Fungoides and Sézary Syndrome Oleg Akilov, University of Pittsburgh
HiJAKing Cutaneous Cytotoxic T Cell Lymphomas Jaehyuk Choi, Northwestern University
E7777-IL2 Fusion Toxin Madeleine Duvic , MD Anderson Cancer Center
CD70-targeted agents in Cutaneous T-Cell Lymphoma Swami Iyer, MD Anderson Cancer Center
Break
Bench to Bedside - Part 2 *Jasmine Zain, City of Hope
Photodynamic therapy for CTCL Ellen Kim, University of Pennsylvania
CD30/CCR4 CAR-T Cell in Cutaneous T- Cell Lymphoma Natalie Grover, University of North Carolina
<i>KIR3DL2 antibody in CTCL</i> Pierluigi Porcu , Jefferson University
PI3Kinase Inhibitors in CTCL Neha Mehta-Shah, Washington University St. Louis
Novel insights from the immunobiology of CTCL Rachael Clark , Harvard University
Panel & Audience Polling: Looking to the Future *Susan Thornton, Cutaneous Lymphoma Foundation, *John Zic, Vanderbilt University
Adjourn/Closing Comments *John Zic, Vanderbilt University

2:52-3:20

3:20-4:20

4:20 - 4:50

4:50 - 5:00